P3 Reagent Kit Expands Potential of Illumina’s NextSeq 2000 Kumar Jeetendra | November 14, 2020 Illumina, San Diego, has expanded the reach of this NextSeq2000 Sequencing System with the commercial access to the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost 3 times greater than previously accessible on Illumina’s mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run …
Access to Whole-Genome Sequencing for Genetic Disease Testing :Illumina and Harvard Pilgrim Health Care Kumar Jeetendra | December 20, 2020 SAN DIEGO & WELLESLEY, Mass.–(BUSINESS WIRE)– Illumina, Inc. (Nasdaq: ILMN) and Harvard Pilgrim Health Care announce a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January 1, 2021. The program will leverage WGS to support faster diagnoses of genetic diseases in children, potentially eliminating the long, costly diagnostic odyssey …
Illumina’s NextSeq 550Dx platform and associated reagent kits received medical device registration in Russia Kumar Jeetendra | March 13, 2021 San Diego-based Illumina’s NextSeq 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeqDx which was approved previously as a medical device. Both of these in vitro diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology. These registrations will …
